Revance Therapeutics (NASDAQ:RVNC) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note published on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. Piper Sandler cut shares of Revance Therapeutics from a strong-buy rating to a hold rating in a research note on Monday, August 12th. HC Wainwright cut shares of Revance Therapeutics from a strong-buy rating to a hold rating in a research note on Tuesday, August 13th. William Blair reissued a market perform rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Guggenheim reissued a neutral rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Finally, Stifel Nicolaus dropped their price objective on shares of Revance Therapeutics from $24.00 to $20.00 and set a buy rating for the company in a report on Friday, August 9th. Ten analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, Revance Therapeutics presently has an average rating of Hold and a consensus target price of $10.50.

Revance Therapeutics Stock Performance

NASDAQ:RVNC opened at $5.30 on Monday. The firm’s 50-day moving average is $5.42 and its 200-day moving average is $4.27. Revance Therapeutics has a 52-week low of $2.30 and a 52-week high of $13.12. The company has a market cap of $555.55 million, a price-to-earnings ratio of -1.46 and a beta of 1.00.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.12. The company had revenue of $65.39 million for the quarter, compared to the consensus estimate of $66.30 million. During the same quarter in the previous year, the firm posted ($0.80) EPS. The business’s revenue for the quarter was up 20.2% compared to the same quarter last year.

Institutional Investors Weigh In On Revance Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in RVNC. Arizona State Retirement System increased its position in Revance Therapeutics by 27.6% in the second quarter. Arizona State Retirement System now owns 27,716 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 5,996 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of Revance Therapeutics by 67.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 16,981 shares of the biopharmaceutical company’s stock worth $84,000 after buying an additional 6,826 shares during the last quarter. Sei Investments Co. lifted its holdings in Revance Therapeutics by 52.5% in the second quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 7,628 shares during the period. California State Teachers Retirement System boosted its stake in Revance Therapeutics by 9.8% in the first quarter. California State Teachers Retirement System now owns 97,493 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 8,668 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in Revance Therapeutics during the 4th quarter worth $84,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.